Skip to main content

Outcomes

TOPKAT Trial: Partial vs Total Knee Replacement

MedPage Today

Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after 10 years in a randomized trial -- and maybe a little bit better.

Read Article
Longitudinal study of 1761 US military service pre- & post-deployment. The prevalence of fibromyalgia in Males/Females was 2.%/2% (sames as civilians) but post-deploy incr to 8%/11% (P < 0.001). PTSD incr from 21% /18% to 23%/26%. PTSD predeployment lead to a 3 fold risk of FM. https://t.co/XTjuhjx0zd
Dr. John Cush @RheumNow( View Tweet )
Multinational retrospective review of CV risk in IIM (myositis) cohorts finds among 336 pts that > 1/3 are at moderate-high risk for CVD - but 34 % prescribed a statin. Moderate-high risk scores seen w/ necrotizing myopathy (OR 4.6), steroids (OR 1.8), dyslipidaemia (1.2) https://t.co/4IMiaHJvL3
Dr. John Cush @RheumNow( View Tweet )
Clinical contributors to pathogenesis and treatment outcomes for rheumatoid arthritis. Full read review of pathogenesis and unmet needs in #RA https://t.co/OZxOuXdnIq https://t.co/LuYoLVfb7N
Dr. John Cush @RheumNow( View Tweet )
Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa
Dr. John Cush @RheumNow( View Tweet )
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?

Dr. John Cush @RheumNow( View Tweet )

Treat-to-Target in Gout and Cardiovascular Outcomes

A 5 year JAMA study shows that a treat-to-target (serum urate < 6 mg/dL) study finds that effective urate-lowering treatment (ULT) results in a significantly reduced cardiovascular risk in patients with gout. 

These findinds are significant knowing that

Read Article
New content online: Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials https://t.co/nDxfWWgutC https://t.co/Z6JMojdBz4
NatRevRheumatol @NatRevRheumatol( View Tweet )
Rheum Poll> Which is the most difficult to treat RA (D2TRA) patient (despite aggressive Rx)?

Dr. John Cush @RheumNow( View Tweet )

APPIPRA Study - Benefits of Early Treatment Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped. https://t.co/hgxj936CWn https://t.co/eJX3amp3Id
Dr. John Cush @RheumNow( View Tweet )

Trends in Rheumatoid Arthritis Mortality

A recent study examines trends in rheumatoid arthritis (RA)-related mortality among U.S. postmenopausal women (aged 55 and older). They found RA mortality rates have declined, yet disparities in who is most affected persist, especially for white women, and those over 85 yrs of age.

Read Article

Reduced Healthy Working Life Expectancy with Arthritis

MedPage Today

Using the long-running, U.S.-based Health and Retirement Study (HRS), which enrolls people age 50 and older, as the data source, Ross Wilkie, PhD, of Keele University in Staffordshire, England, and colleagues estimated that those reporting an arthritis diagnosis could expect just 6.18 more years

Read Article
UCAN CAN-DU study of 181 JIA pts starting biologics. Early Rx w/in 6 mos (n=35) assoc. w/ greater odds of achieving inactive arthritis (83% vs 57% in late starters (>12 mos). For each month of delay increased the odds of future active arthritis (after 6 mos) by 9%.

Dr. John Cush @RheumNow( View Tweet )

Emergencies, Independence & Hemorrhage (1.23.2026)

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Read Article

BIOBADASER III Registry shows No Cancer Risk with b/tsDMARDs

A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer. 

Researchers used 2000–2023 data for RA patients from the BIOBADASER III registry,

Read Article

APPIPRA Study - Benefits of Early Treatment

EurekAlert!

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.

Read Article
Preoperative Semaglutide for 3 mos. prior to Total Knee Arthroplasty assoc w/ signif less Postoperative Adverse Events in NIDDM. Retrospective study of up to 745 T2DM needed TKR . 2-3 mos of GLP-1a reduces serious AEs by 75% (OR 0.25, P < 0.001). https://t.co/re57y9OvTN https://t.co/KNirmfdr2F
Dr. John Cush @RheumNow( View Tweet )
Emergency Department Visits by Rheumatoid Patients A Canadian population study shows that rheumatoid arthritis (RA) patients have 30% higher emergency department (ED) visit rates for Ambulatory Care Sensitive Conditions (ACSCs) compared to age- and sex-matched population https://t.co/BL8AkXhkFG
Dr. John Cush @RheumNow( View Tweet )
Smartphones and Rheumatoid Flares FORWARD Databank of Rheumatoid arthritis (RA) patients reveals that smartphone data can predict flares using PROs. https://t.co/xy6uqsQNt2 https://t.co/JwZlOLco6V
Dr. John Cush @RheumNow( View Tweet )

Are JAK Inhibitors Better at Pain Relief in RA?

MedPage Today

Among rheumatoid arthritis (RA) patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.

Read Article

Review of Restless Legs Syndrome

JAMA has published a full read review of RLS - restless leg syndrome - a frequent, but often unrecognized, cause of poor sleep and the resultant hazards of insomnia.

Read Article

Emergency Department Visits by Rheumatoid Patients

A Canadian population study shows that rheumatoid arthritis (RA) patients have 30% higher emergency department (ED) visit rates for Ambulatory Care Sensitive Conditions (ACSCs) compared to age- and sex-matched population controls.

Read Article

Smartphones and Rheumatoid Flares

FORWARD Databank of Rheumatoid arthritis (RA) patients reveals that smartphone data can predict flares using PROs. 

RA flares are seen in 30-60% of patients, are hard

Read Article

Nurse Practitioner Independence

A JAMA Viewpoint article reports on a March 2025 Nurse Practitioner (NP) Entrepreneurship Summit in Boston in March 2025 identifying barriers and opportunities to NP-owned medical practices.

Read Article
In Dec 2025, the FDA qualified total hip bone mineral density (BMD) assessed by DXA as a validated surrogate endpoint for osteoporosis clinical trials. Previously OP trials required fracture endpoints as primary efficacy measures, necessitating large 2-5 yr studies https://t.co/5t9rftwX4A
Dr. John Cush @RheumNow( View Tweet )
×